Fig. 3From: Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal riskProposed renal-protective pathways with SGLT2 inhibitors. CTCF connective tissue growth factor; ICAM-1, intercellular adhesion molecule 1; NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells; MCP-1 monocyte chemoattractant protein 1; SGLT2 sodium–glucose cotransporter 2; TGF-β transforming growth factor betaBack to article page